Fernandez-Avilés Francisco, Alonso Joaquín J, Castro-Beiras Alfonso, Vázquez Nicolás, Blanco Jesús, Alonso-Briales Juan, López-Mesa Juan, Fernández-Vazquez Felipe, Calvo Isabel, Martínez-Elbal Luis, San Román José A, Ramos Benigo
Instituto de Ciencias del Corazón, Hospital Universitario, Valladolid, Spain.
Lancet. 2004;364(9439):1045-53. doi: 10.1016/S0140-6736(04)17059-1.
In patients with ST-segment elevated myocardial infarction (STEMI), early post-thrombolysis routine angioplasty has been discouraged because of its association with high incidence of events. The GRACIA-1 trial was designed to reassess the benefits of an early post-thrombolysis interventional approach in the era of stents and new antiplatelet agents.
500 patients with thrombolysed STEMI (with recombinant tissue plasminogen activator) were randomly assigned to angiography and intervention if indicated within 24 h of thrombolysis, or to an ischaemia-guided conservative approach. The primary endpoint was the combined rate of death, reinfarction, or revascularisation at 12 months. Analysis was by intention to treat.
Invasive treatment included stenting of the culprit artery in 80% (199 of 248) patients, bypass surgery in six (2%), non-culprit artery stenting in three, and no intervention in 40 (16%). Predischarge revascularisation was needed in 51 of 252 patients in the conservative group. By comparison with patients receiving conservative treatment, by 1 year, patients in the invasive group had lower frequency of primary endpoint (23 [9%] vs 51 [21%], risk ratio 0.44 [95% CI 0.28-0.70], p=0.0008), and they tended to have reduced rate of death or reinfarction (7% vs 12%, 0.59 [0.33-1.05], p=0.07). Index time in hospital was shorter in the invasive group, with no differences in major bleeding or vascular complications. At 30 days both groups had a similar incidence of cardiac events. In-hospital incidence of revascularisation induced by spontaneous recurrence of ischaemia was higher in patients in the conservative group than in those in the invasive group.
In patients with STEMI, early post-thrombolysis catheterisation and appropriate intervention is safe and might be preferable to a conservative strategy since it reduces the need for unplanned in-hospital revascularisation, and improves 1-year clinical outcome.
在ST段抬高型心肌梗死(STEMI)患者中,溶栓后早期常规血管成形术因与高事件发生率相关而不被提倡。GRACIA - 1试验旨在重新评估在支架和新型抗血小板药物时代溶栓后早期介入治疗方法的益处。
500例接受重组组织型纤溶酶原激活剂溶栓治疗的STEMI患者被随机分配,若在溶栓后24小时内有指征则接受血管造影和介入治疗,或采用缺血指导的保守治疗方法。主要终点是12个月时死亡、再梗死或血管重建的综合发生率。分析采用意向性治疗。
侵入性治疗包括80%(248例中的199例)患者对罪犯血管进行支架置入,6例(2%)患者进行搭桥手术,3例对非罪犯血管进行支架置入,40例(16%)患者未进行干预。保守治疗组252例患者中有51例需要出院前血管重建。与接受保守治疗的患者相比,到1年时,侵入性治疗组患者主要终点发生率较低(23例[9%]对51例[21%],风险比0.44[95%CI 0.28 - 0.70],p = 0.0008),且死亡或再梗死发生率有降低趋势(7%对12%,0.59[0.33 - 1.05],p = 0.07)。侵入性治疗组住院时间较短,在大出血或血管并发症方面无差异。30天时两组心脏事件发生率相似。保守治疗组患者因缺血自发复发导致的住院血管重建发生率高于侵入性治疗组。
在STEMI患者中,溶栓后早期导管插入术及适当干预是安全的,可能优于保守策略,因为它减少了计划外住院血管重建的需求,并改善了1年临床结局。